Belgian Cancer Registry

CANCER FACT SHEET 2024
CORPUS UTERI CANCER
ICD-10 C54

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Corpus uteri cancer incidence: by region 5

1.1.1. Corpus uteri cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Corpus uteri cancer incidence: by tumour stage 6

1.2.1. Corpus uteri cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 6

1.2.2. Corpus uteri cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 6

1.2.3. Corpus uteri cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.4. Corpus uteri cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.5. Corpus uteri cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

2. CANCER INCIDENCE TRENDS 9

2.1. Corpus uteri cancer incidence trends: by region 9

2.1.1. Corpus uteri cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 9

2.2. Corpus uteri cancer incidence trends: by tumour stage 10

2.2.1. Corpus uteri cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 10

2.3. Corpus uteri cancer incidence trends: by tumour type 11

2.3.1. Corpus uteri cancer incidence trends by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 11

2.4. Corpus uteri cancer incidence trends: by age group 12

2.4.1. Corpus uteri cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 12

3. CANCER PREVALENCE 13

3.1. Corpus uteri cancer prevalence: by region 13

3.1.1. Corpus uteri cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 13

4. CANCER SURVIVAL 14

4.1. Corpus uteri cancer survival: by region 14

4.1.1. Corpus uteri cancer survival by region and age group: number at risk and net survival probabilities, 2020-2024 14

4.2. Corpus uteri cancer survival: by tumour type and tumour stage 16

4.2.1. Corpus uteri cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2020-2024 16

4.2.2. Corpus uteri cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2020-2024 18

4.2.3. Corpus uteri cancer survival by type and stage: number at risk and net survival probabilities, 2020-2024 19
5. CANCER SURVIVAL TRENDS 21
5.1. Corpus uteri cancer survival trends: by tumour stage 21
5.1.1. Corpus uteri cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024 21
5.2. Corpus uteri cancer survival trends: by tumour type and tumour stage 23
5.2.1. Corpus uteri cancer survival trends by type and stage: number at risk and net survival probabilities, 2004-2024 23
6. CANCER MORTALITY 27
6.1. Corpus uteri cancer mortality: by region 27
6.1.1. Corpus uteri cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 27
7. CANCER MORTALITY TRENDS 28
7.1. Corpus uteri cancer mortality trends: by region 28
7.1.1. Corpus uteri cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 28

1.1. Corpus uteri cancer incidence: by region

1.1.1. Corpus uteri cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Females																						
Belgium	0	0	0	0	0	3	6	10	14	22	66	106	159	238	223	220	133	89	38	8	1,335	20.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.5]	[2.6]	[3.6]	[5.9]	[17.1]	[27.0]	[41.2]	[69.0]	[74.7]	[85.9]	[76.5]	[65.7]	[52.7]	[37.0]	[22.4]	(19.7; 21.9)
Brussels	0	0	0	0	0	1	1	3	1	2	8	9	12	22	13	16	5	4	3	1	101	20.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[1.8]	[6.2]	[2.2]	[4.8]	[20.8]	[26.2]	[39.3]	[87.5]	[60.4]	[86.3]	[39.0]	[41.5]	[53.2]	[47.6]	[15.8]	(16.1; 24.0)
Flanders	0	0	0	0	0	0	2	5	10	16	35	59	99	136	125	131	86	58	18	2	782	20.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.3]	[4.5]	[7.6]	[15.8]	[25.3]	[42.7]	[65.8]	[70.6]	[84.7]	[78.5]	[66.9]	[39.7]	[15.5]	[22.7]	(18.8; 21.7)
Wallonia	0	0	0	0	0	2	3	2	3	4	23	38	48	80	85	73	42	27	17	5	452	21.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[2.5]	[1.7]	[2.5]	[3.4]	[18.3]	[30.4]	[38.8]	[70.7]	[85.1]	[88.2]	[81.6]	[69.0]	[80.5]	[75.4]	[24.0]	(19.9; 24.0)

1.2. Corpus uteri cancer incidence: by tumour stage

1.2.1. Corpus uteri cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+	
I	72 [2.4]	496 [34.9]	291 [44.2]	859 [14.4]	13.5 (12.6; 14.4)
II	6 [0.2]	31 [2.2]	28 [4.2]	65 [1.1]	1.0 (0.8; 1.2)
III	6 [0.2]	55 [3.9]	47 [7.1]	108 [1.8]	1.6 (1.3; 1.9)
IV	6 [0.2]	57 [4.0]	56 [8.5]	119 [2.0]	1.8 (1.5; 2.2)
X/NA	31 [1.1]	87 [6.1]	66 [10.0]	184 [3.1]	2.8 (2.4; 3.3)

1.2.2. Corpus uteri cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+	
I	84 [2.8]	522 [36.7]	260 [39.4]	866 [14.5]	13.7 (12.8; 14.6)
II	5 [0.2]	34 [2.4]	37 [5.6]	76 [1.3]	1.2 (0.9; 1.4)
III	9 [0.3]	83 [5.8]	64 [9.7]	156 [2.6]	2.4 (2.1; 2.8)
IV	4 [0.1]	25 [1.8]	14 [2.1]	43 [0.7]	0.7 (0.5; 0.9)
X/NA	19 [0.6]	62 [4.4]	113 [17.1]	194 [3.3]	2.8 (2.4; 3.2)

1.2.3. Corpus uteri cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+	
I	90 [3.1]	526 [37.0]	280 [42.5]	896 [15.0]	14.1 (13.2; 15.0)
II	5 [0.2]	35 [2.5]	41 [6.2]	81 [1.4]	1.2 (1.0; 1.5)
III	10 [0.3]	89 [6.3]	83 [12.6]	182 [3.1]	2.8 (2.4; 3.2)
IV	7 [0.2]	63 [4.4]	58 [8.8]	128 [2.1]	2.0 (1.6; 2.3)
X/NA	9 [0.3]	13 [0.9]	26 [3.9]	48 [0.8]	0.7 (0.5; 0.9)

1.2.4. Corpus uteri cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+	
Endometrioid carcinoma	92 [3.1]	545 [38.3]	329 [49.9]	966 [16.2]	15.1 (14.2; 16.1)
Serous carcinoma	1 [0.0]	83 [5.8]	78 [11.8]	162 [2.7]	2.5 (2.1; 2.9)
Other and unspecified	28 [0.9]	98 [6.9]	81 [12.3]	207 [3.5]	3.2 (2.7; 3.6)

1.2.5. Corpus uteri cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

		N[CR]				ESR2013 (95%CI)
Type	**Stage**	**15-54**	**55-74**	**75+**	**All ages 0+**	
Endometrioid carcinoma	I	77 [2.6]	441 [31.0]	221 [33.5]	739 [12.4]	11.7 (10.8; 12.5)
	II	4 [0.1]	19 [1.3]	30 [4.6]	53 [0.9]	0.8 (0.6; 1.0)
	III	7 [0.2]	50 [3.5]	44 [6.7]	101 [1.7]	1.6 (1.3; 1.9)
	IV	2 [0.1]	26 [1.8]	27 [4.1]	55 [0.9]	0.8 (0.6; 1.1)
	X/NA	2 [0.1]	9 [0.6]	7 [1.1]	18 [0.3]	0.3 (0.1; 0.4)
Serous carcinoma	I	0 [0.0]	38 [2.7]	28 [4.2]	66 [1.1]	1.0 (0.8; 1.3)
	II	0 [0.0]	4 [0.3]	5 [0.8]	9 [0.2]	0.1 (0.0; 0.2)
	III	0 [0.0]	22 [1.5]	25 [3.8]	47 [0.8]	0.7 (0.5; 0.9)
	IV	0 [0.0]	18 [1.3]	15 [2.3]	33 [0.6]	0.5 (0.3; 0.7)
	X/NA	1 [0.0]	1 [0.1]	5 [0.8]	7 [0.1]	0.1 (0.0; 0.2)
Other and unspecified	I	13 [0.4]	47 [3.3]	31 [4.7]	91 [1.5]	1.4 (1.1; 1.7)
	II	1 [0.0]	12 [0.8]	6 [0.9]	19 [0.3]	0.3 (0.2; 0.4)
	III	3 [0.1]	17 [1.2]	14 [2.1]	34 [0.6]	0.5 (0.4; 0.7)
	IV	5 [0.2]	19 [1.3]	16 [2.4]	40 [0.7]	0.6 (0.4; 0.8)
	X/NA	6 [0.2]	3 [0.2]	14 [2.1]	23 [0.4]	0.3 (0.2; 0.5)

2.1. Corpus uteri cancer incidence trends: by region

2.1.1. Corpus uteri cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	1,432	1,382	1,348	1,393	1,466	1,462	1,419	1,430	1,453	1,391	1,464	1,458	1,446	1,401	1,442	1,347	1,308	1,422	1,381	1,414	1,335		
	CR	27.0	25.9	25.1	25.8	26.9	26.7	25.7	25.6	25.8	24.6	25.8	25.6	25.2	24.3	25.0	23.2	22.4	24.3	23.5	23.8	22.4		
	ESR2013	28.1	26.9	26.1	26.6	27.5	27.2	26.0	26.0	26.1	24.4	25.5	25.3	25.0	23.7	24.1	22.3	21.3	22.9	22.1	22.2	20.8	-1.3 (-1.6; -1.1)	2004-2024
																							-0.9 (-1.3; -0.5)	2004-2015
																							-1.9 (-2.4; -1.4)	2016-2024
Brussels	**N**	111	105	102	105	116	122	113	100	80	125	106	109	115	111	122	95	99	133	104	104	101		
	CR	21.4	20.1	19.3	19.6	21.4	22.1	20.1	17.3	13.7	21.1	17.8	18.1	18.9	18.2	19.9	15.4	16.0	21.4	16.7	16.4	15.8		
	ESR2013	23.8	22.6	21.9	22.9	24.4	25.8	23.9	20.5	16.9	25.8	21.5	22.2	23.9	22.7	25.1	18.6	19.6	26.8	21.3	20.4	20.1	-0.5 (-1.3; 0.4)	2004-2024
Flanders	**N**	863	830	838	859	911	894	830	859	920	855	881	887	872	838	831	834	799	854	858	840	782		
	CR	28.3	27.1	27.2	27.7	29.2	28.4	26.2	26.9	28.6	26.5	27.1	27.2	26.6	25.4	25.1	25.1	23.9	25.4	25.4	24.5	22.7		
	ESR2013	29.0	27.4	27.6	27.9	29.0	28.2	25.7	26.3	27.9	25.1	25.8	25.9	25.1	23.8	23.0	23.0	21.7	22.7	22.9	21.7	20.2	-1.6 (-1.9; -1.3)	2004-2024
Wallonia	**N**	458	447	408	429	439	446	476	471	453	411	477	462	459	452	489	418	410	435	419	470	452		
	CR	26.3	25.6	23.2	24.3	24.7	25.0	26.5	26.0	24.9	22.5	26.0	25.1	24.9	24.4	26.4	22.5	22.0	23.3	22.4	25.0	24.0		
	ESR2013	27.7	27.0	24.6	25.1	25.5	25.5	26.9	26.7	25.4	22.8	25.8	24.9	25.0	23.6	25.6	21.8	20.9	22.1	20.9	23.4	21.9	-1.1 (-1.5; -0.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Corpus uteri cancer incidence trends: by tumour stage

2.2.1. Corpus uteri cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Stage		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
I	N	886	977	935	963	896		
	CR	15.2	16.7	15.9	16.2	15.0		
	ESR2013	14.6	16.0	15.1	15.2	14.1	0.5 (0.2; 0.9)	2004-2024
							4.5 (3.4; 5.6)	2004-2011
							-0.8 (-2.4; 0.8)	2012-2015
							-1.8 (-2.6; -1.0)	2016-2024
II	N	64	77	84	81	81		
	CR	1.1	1.3	1.4	1.4	1.4		
	ESR2013	1.0	1.2	1.3	1.2	1.2	-2.1 (-2.8; -1.3)	2004-2024
							-3.7 (-5.2; -2.1)	2004-2015
							0.0 (-2.0; 2.0)	2016-2024
III	N	162	171	173	178	182		
	CR	2.8	2.9	2.9	3.0	3.1		
	ESR2013	2.7	2.7	2.7	2.8	2.8	0.6 (-0.1; 1.3)	2004-2024
IV	N	123	129	133	144	128		
	CR	2.1	2.2	2.3	2.4	2.1		
	ESR2013	2.0	2.0	2.1	2.2	2.0	3.5 (2.6; 4.5)	2004-2024
X/NA	N	73	68	56	48	48		
	CR	1.3	1.2	1.0	0.8	0.8		
	ESR2013	1.1	1.0	0.9	0.7	0.7	-12.2 (-13.1; -11.4)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Corpus uteri cancer incidence trends: by tumour type

2.3.1. Corpus uteri cancer incidence trends by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Type		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Endometrioid carcinoma	**N**	885	861	868	905	982	1,033	943	1,002	1,041	985	1,041	1,044	1,023	1,016	1,026	968	958	1,033	988	1,041	966		
	CR	16.7	16.1	16.2	16.7	18.0	18.8	17.1	18.0	18.5	17.4	18.3	18.3	17.9	17.7	17.8	16.7	16.4	17.7	16.8	17.5	16.2		
	ESR2013	17.5	16.9	16.9	17.4	18.5	19.2	17.4	18.3	18.8	17.4	18.2	18.3	17.9	17.2	17.2	16.1	15.7	16.7	15.9	16.4	15.1	-0.6 (-0.9; -0.3)	2004-2024
																							0.6 (0.0; 1.2)	2004-2014
																							-1.8 (-2.4; -1.2)	2015-2024
Serous carcinoma	**N**	47	52	53	74	78	98	83	91	93	96	114	110	128	119	148	117	123	145	147	149	162		
	CR	0.9	1.0	1.0	1.4	1.4	1.8	1.5	1.6	1.7	1.7	2.0	1.9	2.2	2.1	2.6	2.0	2.1	2.5	2.5	2.5	2.7		
	ESR2013	0.9	1.0	1.0	1.4	1.4	1.8	1.5	1.6	1.7	1.7	2.0	1.9	2.2	2.0	2.4	1.9	2.0	2.3	2.4	2.3	2.5	5.3 (4.5; 6.2)	2004-2024
																							13.3 (8.9; 17.9)	2004-2009
																							2.5 (-1.5; 6.6)	2010-2013
																							2.9 (1.4; 4.4)	2014-2024
Other and unspecified	**N**	500	469	427	414	406	331	393	337	319	310	309	304	295	266	268	262	227	244	246	224	207		
	CR	9.4	8.8	8.0	7.7	7.5	6.0	7.1	6.0	5.7	5.5	5.4	5.3	5.1	4.6	4.6	4.5	3.9	4.2	4.2	3.8	3.5		
	ESR2013	9.8	9.0	8.2	7.8	7.5	6.1	7.2	6.0	5.6	5.3	5.3	5.1	5.0	4.4	4.5	4.2	3.7	3.9	3.9	3.5	3.2	-5.2 (-5.6; -4.8)	2004-2024
																							-6.6 (-8.1; -5.1)	2004-2010
																							-4.6 (-5.1; -4.0)	2011-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Corpus uteri cancer incidence trends: by age group

2.4.1. Corpus uteri cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
15-54	**N**	161	154	158	160	162	156	148	140	122	141	151	157	148	129	127	120	105	120	131	123	121			
	CR	5.7	5.5	5.6	5.6	5.7	5.4	5.1	4.8	4.2	4.8	5.2	5.4	5.1	4.5	4.4	4.2	3.6	4.2	4.5	4.2	4.1			
	ESR2013	6.0	5.7	5.7	5.7	5.7	5.5	5.1	4.8	4.2	4.8	5.1	5.4	5.0	4.4	4.4	4.2	3.7	4.2	4.6	4.3	4.2	-1.8	(-2.4; -1.2)	2004-2024
55-74	**N**	854	804	813	812	820	836	785	806	857	744	772	820	801	775	825	744	720	772	735	750	726			
	CR	78.0	72.8	73.2	72.7	72.8	73.3	67.9	68.6	71.8	61.4	62.8	65.6	62.8	59.4	62.0	54.9	52.3	55.4	52.4	53.0	51.1			
	ESR2013	78.0	73.1	73.7	73.3	73.6	74.1	69.2	69.9	73.2	62.7	64.3	67.0	64.7	60.7	62.9	55.6	52.8	55.7	52.8	53.2	51.1	-2.1	(-2.4; -1.8)	2004-2024
																							-1.6	(-2.1; -1.1)	2004-2016
																							-2.9	(-3.8; -2.1)	2017-2024
75+	**N**	417	424	377	421	484	470	486	484	474	506	541	481	497	497	490	483	483	530	515	541	488			
	CR	80.2	79.8	69.2	75.5	85.0	81.3	82.8	81.6	79.0	83.7	88.7	77.9	80.6	81.1	80.2	78.6	77.8	85.6	81.2	83.8	74.0			
	ESR2013	78.8	78.9	68.7	75.2	84.6	80.9	82.6	82.2	79.0	83.6	89.6	78.8	83.3	82.7	81.8	81.3	81.2	87.3	84.5	85.7	75.9	0.4	(0.0; 0.8)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Corpus uteri cancer prevalence: by region

3.1.1. Corpus uteri cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Females				
		1-year	5-year	10-year	15-year	20-year
Belgium	**N**	1,245	5,564	9,980	13,460	16,179
	CR	20.8	92.8	166.5	224.5	269.9
	ESR2013	19.2	84.8	150.9	201.4	239.8
Brussels	**N**	90	420	748	966	1,133
	CR	14.1	65.6	116.8	150.8	176.9
	ESR2013	17.9	82.0	146.3	188.2	220.3
Flanders	**N**	731	3,376	6,090	8,305	10,052
	CR	21.1	97.4	175.8	239.7	290.1
	ESR2013	18.7	85.0	151.7	204.3	244.8
Wallonia	**N**	424	1,768	3,142	4,189	4,994
	CR	22.4	93.5	166.2	221.6	264.2
	ESR2013	20.3	84.6	149.5	197.7	233.9

4.1. Corpus uteri cancer survival: by region

4.1.1. Corpus uteri cancer survival by region and age group: number at risk and net survival probabilities, 2020-2024

			Net Survival Probability, 2020-2024		
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**
Females					
Belgium	**All ages 15+**	13,907	91.3% (90.7%; 91.8%)	84.0% (83.2%; 84.8%)	81.3% (80.3%; 82.4%)
	15-54	1,114	96.2% (95.1%; 97.4%)	91.2% (89.4%; 92.9%)	88.7% (86.6%; 90.7%)
	55-74	7,650	94.3% (93.8%; 94.9%)	87.8% (86.9%; 88.6%)	84.8% (83.8%; 85.9%)
	75+	4,988	85.4% (84.2%; 86.6%)	76.5% (74.8%; 78.2%)	74.1% (71.8%; 76.5%)
Brussels	**All ages 15+**	1,081	90.1% (88.1%; 92.2%)	82.3% (79.4%; 85.3%)	80.0% (76.4%; 83.8%)
	15-54	145	94.6% (90.9%; 98.4%)	89.1% (84.0%; 94.5%)	86.7% (80.9%; 92.9%)
	55-74	563	93.3% (91.1%; 95.6%)	85.3% (82.0%; 88.7%)	82.4% (78.5%; 86.4%)
	75+	359	83.3% (78.7%; 88.1%)	74.7% (68.3%; 81.7%)	73.3% (64.9%; 82.7%)
Flanders	**All ages 15+**	8,371	91.4% (90.7%; 92.1%)	84.2% (83.1%; 85.2%)	81.8% (80.5%; 83.1%)
	15-54	608	96.5% (95.0%; 98.0%)	90.8% (88.4%; 93.2%)	88.4% (85.7%; 91.3%)
	55-74	4,533	94.7% (94.0%; 95.4%)	88.0% (86.9%; 89.0%)	85.4% (84.1%; 86.7%)
	75+	3,134	85.3% (83.8%; 86.8%)	77.2% (75.0%; 79.3%)	75.2% (72.3%; 78.1%)
Wallonia	**All ages 15+**	4,455	91.4% (90.5%; 92.4%)	84.1% (82.6%; 85.5%)	80.6% (78.7%; 82.6%)
	15-54	361	96.3% (94.3%; 98.3%)	92.7% (89.9%; 95.6%)	89.8% (86.4%; 93.5%)

Net Survival Probability, 2020-2024					
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**
	55-74	2,554	93.9% (92.9%; 94.9%)	88.0% (86.5%; 89.5%)	84.4% (82.5%; 86.3%)
	75+	1,495	85.9% (83.8%; 88.2%)	75.4% (72.2%; 78.8%)	72.1% (67.7%; 76.9%)

4.2. Corpus uteri cancer survival: by tumour type and tumour stage

4.2.1. Corpus uteri cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2020-2024

			Net Survival Probability, 2020-2024				
Type	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**
Corpus uteri	All	13,907	91.3% (90.7%; 91.8%)	86.8% (86.1%; 87.5%)	84.0% (83.2%; 84.8%)	82.3% (81.4%; 83.3%)	81.3% (80.3%; 82.4%)
	I	6,959	98.9% (98.4%; 99.3%)	97.6% (96.9%; 98.2%)	95.8% (94.9%; 96.8%)	94.7% (93.6%; 95.9%)	93.9% (92.5%; 95.3%)
	II	474	92.0% (89.0%; 95.1%)	83.8% (79.7%; 88.1%)	79.2% (74.3%; 84.3%)	75.9% (70.5%; 81.8%)	74.3% (68.2%; 81.0%)
	III	986	80.0% (77.3%; 82.7%)	68.2% (65.0%; 71.6%)	60.1% (56.6%; 63.8%)	55.9% (52.2%; 59.9%)	54.4% (50.4%; 58.8%)
	IV	993	47.3% (44.3%; 50.7%)	32.4% (29.5%; 35.7%)	24.8% (22.0%; 27.9%)	20.6% (17.9%; 23.7%)	18.3% (15.6%; 21.5%)
	X/NA	4,501	91.6% (90.7%; 92.6%)	86.5% (85.3%; 87.7%)	84.3% (83.0%; 85.7%)	83.0% (81.5%; 84.6%)	82.0% (80.3%; 83.7%)
Endometrioid carcinoma	All	10,043	96.5% (96.0%; 97.0%)	94.8% (94.1%; 95.4%)	93.4% (92.6%; 94.2%)	92.4% (91.4%; 93.3%)	91.9% (90.8%; 93.1%)
	I	5,625	100.1% (99.7%; 100.5%)	100.3% (99.7%; 100.9%)	99.7% (98.9%; 100.6%)	99.4% (98.3%; 100.5%)	98.8% (97.4%; 100.2%)
	II	298	95.8% (92.7%; 99.0%)	89.9% (85.2%; 94.8%)	86.5% (80.8%; 92.5%)	83.5% (77.0%; 90.7%)	84.3% (77.1%; 92.2%)
	III	565	86.8% (83.7%; 90.0%)	78.6% (74.8%; 82.7%)	72.9% (68.5%; 77.6%)	68.8% (63.9%; 74.1%)	69.0% (63.6%; 75.0%)
	IV	395	57.3% (52.5%; 62.6%)	43.6% (38.7%; 49.1%)	35.9% (31.0%; 41.5%)	30.6% (25.7%; 36.4%)	29.7% (24.7%; 35.7%)
	X/NA	3,160	96.6% (95.8%; 97.5%)	94.6% (93.4%; 95.8%)	93.6% (92.2%; 95.0%)	92.5% (90.9%; 94.1%)	92.2% (90.3%; 94.0%)
Serous carcinoma	All	1,347	81.1% (78.9%; 83.4%)	65.6% (62.9%; 68.5%)	56.9% (54.0%; 60.1%)	52.0% (48.8%; 55.3%)	48.3% (45.0%; 51.9%)
	I	504	97.4% (95.3%; 99.5%)	86.3% (82.6%; 90.2%)	77.6% (72.9%; 82.5%)	71.6% (66.2%; 77.3%)	69.7% (63.9%; 76.1%)
	II	60	97.4% (91.8%; 103.4%)	80.0% (69.1%; 92.6%)	64.5% (51.5%; 80.6%)	59.2% (45.5%; 77.0%)	48.5% (33.8%; 69.7%)
	III	188	75.5% (69.2%; 82.3%)	56.1% (48.9%; 64.3%)	45.8% (38.5%; 54.4%)	41.0% (33.6%; 50.2%)	34.9% (27.2%; 44.9%)
	IV	236	47.4% (41.3%; 54.4%)	29.0% (23.6%; 35.7%)	20.0% (15.2%; 26.4%)	15.3% (10.8%; 21.6%)	10.9% (6.9%; 17.1%)
	X/NA	359	80.6% (76.2%; 85.2%)	63.1% (57.8%; 68.9%)	56.5% (51.0%; 62.6%)	52.7% (47.0%; 59.0%)	49.5% (43.6%; 56.1%)
Other and unspecified	All	2,527	76.1% (74.3%; 77.9%)	66.4% (64.4%; 68.5%)	60.8% (58.6%; 63.1%)	58.4% (56.0%; 60.8%)	56.3% (53.8%; 58.9%)
	I	831	91.2% (89.0%; 93.5%)	85.7% (82.8%; 88.7%)	80.2% (76.7%; 83.8%)	76.5% (72.5%; 80.7%)	74.8% (70.3%; 79.6%)

Net Survival Probability, 2020-2024							
Type	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**
	II	116	78.8% (70.9%; 87.5%)	69.7% (60.4%; 80.3%)	67.2% (57.1%; 79.0%)	63.5% (52.6%; 76.6%)	61.5% (49.3%; 76.8%)
	III	233	67.0% (60.9%; 73.6%)	52.6% (46.1%; 60.0%)	40.5% (34.0%; 48.2%)	36.4% (29.9%; 44.3%)	34.4% (27.9%; 42.5%)
	IV	362	36.4% (31.7%; 41.9%)	22.7% (18.6%; 27.6%)	15.9% (12.4%; 20.6%)	13.3% (9.8%; 18.0%)	10.8% (7.4%; 15.8%)
	X/NA	988	79.6% (76.9%; 82.4%)	69.1% (65.9%; 72.4%)	64.9% (61.5%; 68.4%)	63.6% (60.0%; 67.4%)	61.3% (57.4%; 65.4%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.2. Corpus uteri cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2020-2024

			Net Survival Probability, 2020-2024				
Type	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**
Corpus uteri	All	13,907	91.3% (90.7%; 91.8%)	86.8% (86.1%; 87.5%)	84.0% (83.2%; 84.8%)	82.3% (81.4%; 83.3%)	81.3% (80.3%; 82.4%)
	I	9,156	99.9% (99.6%; 100.2%)	99.3% (98.8%; 99.8%)	98.5% (97.9%; 99.2%)	98.2% (97.3%; 99.0%)	97.9% (96.9%; 99.0%)
	II	711	96.0% (94.1%; 98.0%)	90.3% (87.4%; 93.3%)	86.2% (82.6%; 89.9%)	83.1% (79.0%; 87.4%)	82.2% (77.5%; 87.2%)
	III	1,523	90.2% (88.5%; 91.9%)	79.6% (77.3%; 82.0%)	71.2% (68.5%; 74.0%)	66.4% (63.4%; 69.5%)	62.9% (59.6%; 66.4%)
	IV	507	66.7% (62.6%; 71.1%)	46.3% (42.0%; 51.2%)	36.7% (32.4%; 41.6%)	30.7% (26.5%; 35.6%)	26.6% (22.4%; 31.6%)
	X/NA	2,015	57.6% (55.3%; 59.9%)	44.5% (42.1%; 47.0%)	38.6% (36.2%; 41.2%)	35.1% (32.6%; 37.8%)	33.2% (30.5%; 36.1%)
Endometrioid carcinoma	All	10,043	96.5% (96.0%; 97.0%)	94.8% (94.1%; 95.4%)	93.4% (92.6%; 94.2%)	92.4% (91.4%; 93.3%)	91.9% (90.8%; 93.1%)
	I	7,484	100.8% (100.5%; 101.1%)	101.5% (101.0%; 101.9%)	101.5% (100.9%; 102.1%)	101.7% (100.8%; 102.5%)	101.6% (100.5%; 102.7%)
	II	472	99.3% (97.5%; 101.1%)	96.2% (93.2%; 99.3%)	94.5% (90.7%; 98.4%)	91.4% (86.7%; 96.4%)	92.7% (87.4%; 98.4%)
	III	898	94.2% (92.3%; 96.1%)	89.4% (86.9%; 92.0%)	84.4% (81.2%; 87.6%)	80.2% (76.5%; 84.0%)	77.2% (73.0%; 81.7%)
	IV	149	77.6% (70.8%; 85.0%)	67.1% (59.4%; 75.8%)	58.9% (50.7%; 68.5%)	52.8% (44.1%; 63.1%)	51.1% (42.0%; 62.1%)
	X/NA	1,040	68.6% (65.6%; 71.8%)	54.5% (51.1%; 58.1%)	47.7% (44.1%; 51.6%)	42.6% (38.9%; 46.7%)	41.1% (37.1%; 45.6%)
Serous carcinoma	All	1,347	81.1% (78.9%; 83.4%)	65.6% (62.9%; 68.5%)	56.9% (54.0%; 60.1%)	52.0% (48.8%; 55.3%)	48.3% (45.0%; 51.9%)
	I	537	98.6% (96.8%; 100.4%)	90.9% (87.7%; 94.2%)	84.8% (80.8%; 89.0%)	80.1% (75.4%; 85.1%)	78.3% (73.1%; 83.9%)
	II	86	96.3% (90.8%; 102.1%)	84.8% (75.9%; 94.7%)	71.2% (60.2%; 84.2%)	70.2% (58.4%; 84.3%)	64.0% (51.0%; 80.3%)
	III	287	91.9% (88.3%; 95.7%)	67.7% (62.0%; 73.9%)	53.8% (47.6%; 60.9%)	46.9% (40.4%; 54.4%)	41.4% (34.6%; 49.4%)
	IV	169	67.9% (61.0%; 75.6%)	43.3% (36.1%; 52.0%)	30.8% (24.1%; 39.4%)	20.7% (14.9%; 28.8%)	13.5% (8.6%; 21.3%)
	X/NA	268	37.7% (32.1%; 44.3%)	20.3% (15.8%; 26.2%)	16.1% (11.9%; 21.7%)	15.3% (11.0%; 21.1%)	13.2% (9.0%; 19.5%)
Other and unspecified	All	2,527	76.1% (74.3%; 77.9%)	66.4% (64.4%; 68.5%)	60.8% (58.6%; 63.1%)	58.4% (56.0%; 60.8%)	56.3% (53.8%; 58.9%)
	I	1,140	94.5% (92.8%; 96.1%)	88.9% (86.7%; 91.2%)	85.5% (82.9%; 88.3%)	83.7% (80.7%; 86.8%)	82.7% (79.3%; 86.2%)
	II	153	85.4% (79.4%; 91.9%)	74.9% (67.3%; 83.3%)	68.8% (60.5%; 78.4%)	64.5% (55.5%; 75.0%)	59.9% (50.0%; 71.7%)
	III	338	77.9% (73.3%; 82.7%)	63.4% (58.1%; 69.2%)	50.7% (45.0%; 57.1%)	46.0% (40.0%; 52.8%)	42.8% (36.6%; 50.1%)
	IV	190	56.6% (49.9%; 64.3%)	32.3% (26.1%; 40.0%)	23.8% (18.1%; 31.3%)	22.0% (16.3%; 29.7%)	18.3% (12.8%; 26.2%)
	X/NA	707	48.7% (45.0%; 52.8%)	38.7% (35.0%; 42.9%)	33.7% (29.8%; 38.0%)	31.4% (27.5%; 35.9%)	28.9% (24.8%; 33.8%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.3. Corpus uteri cancer survival by type and stage: number at risk and net survival probabilities, 2020-2024

			Net Survival Probability, 2020-2024				
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**
Corpus uteri	All	13,907	91.3% (90.7%; 91.8%)	86.8% (86.1%; 87.5%)	84.0% (83.2%; 84.8%)	82.3% (81.4%; 83.3%)	81.3% (80.3%; 82.4%)
	I	9,410	99.2% (98.9%; 99.6%)	98.4% (97.8%; 98.9%)	97.3% (96.5%; 98.0%)	96.8% (95.9%; 97.7%)	96.4% (95.3%; 97.5%)
	II	761	92.6% (90.4%; 95.0%)	86.1% (83.0%; 89.4%)	82.0% (78.3%; 85.8%)	78.9% (74.8%; 83.3%)	78.2% (73.6%; 83.1%)
	III	1,692	85.3% (83.5%; 87.2%)	73.9% (71.6%; 76.3%)	66.0% (63.4%; 68.8%)	61.1% (58.3%; 64.2%)	57.8% (54.6%; 61.1%)
	IV	1,195	51.5% (48.6%; 54.5%)	35.0% (32.3%; 38.0%)	27.2% (24.5%; 30.1%)	22.3% (19.8%; 25.2%)	19.4% (16.9%; 22.4%)
	X/NA	854	70.1% (66.8%; 73.5%)	57.9% (54.3%; 61.8%)	54.0% (50.1%; 58.1%)	51.0% (46.9%; 55.4%)	49.6% (45.2%; 54.4%)
Endometrioid carcinoma	All	10,043	96.5% (96.0%; 97.0%)	94.8% (94.1%; 95.4%)	93.4% (92.6%; 94.2%)	92.4% (91.4%; 93.3%)	91.9% (90.8%; 93.1%)
	I	7,667	100.3% (100.0%; 100.7%)	100.6% (100.1%; 101.1%)	100.3% (99.6%; 101.1%)	100.4% (99.5%; 101.2%)	100.2% (99.1%; 101.4%)
	II	501	96.8% (94.6%; 99.1%)	92.4% (89.0%; 95.8%)	89.8% (85.8%; 94.0%)	86.7% (81.9%; 91.8%)	87.9% (82.6%; 93.7%)
	III	990	90.2% (88.1%; 92.4%)	83.5% (80.7%; 86.3%)	78.2% (75.0%; 81.6%)	73.6% (69.9%; 77.5%)	70.8% (66.6%; 75.3%)
	IV	451	60.0% (55.5%; 64.9%)	46.7% (42.0%; 51.8%)	39.2% (34.5%; 44.6%)	33.7% (29.0%; 39.2%)	32.3% (27.4%; 38.0%)
	X/NA	434	79.8% (75.6%; 84.1%)	69.7% (64.7%; 75.0%)	65.9% (60.6%; 71.7%)	61.2% (55.4%; 67.7%)	59.7% (53.4%; 66.8%)
Serous carcinoma	All	1,347	81.1% (78.9%; 83.4%)	65.6% (62.9%; 68.5%)	56.9% (54.0%; 60.1%)	52.0% (48.8%; 55.3%)	48.3% (45.0%; 51.9%)
	I	549	97.8% (95.9%; 99.7%)	90.4% (87.2%; 93.7%)	84.0% (80.0%; 88.3%)	79.4% (74.8%; 84.4%)	77.8% (72.6%; 83.3%)
	II	90	95.7% (90.1%; 101.7%)	81.1% (71.9%; 91.4%)	68.0% (57.0%; 81.0%)	67.0% (55.4%; 81.0%)	61.1% (48.4%; 77.0%)
	III	322	83.9% (79.6%; 88.4%)	61.4% (55.9%; 67.5%)	49.5% (43.6%; 56.1%)	43.4% (37.4%; 50.4%)	38.1% (31.9%; 45.5%)
	IV	299	54.7% (49.2%; 60.8%)	33.4% (28.2%; 39.6%)	23.8% (19.1%; 29.7%)	16.8% (12.6%; 22.3%)	11.2% (7.6%; 16.6%)
	X/NA	87	40.8% (31.3%; 53.2%)	18.4% (11.4%; 29.8%)	15.0% (8.8%; 25.8%)	14.3% (8.1%; 25.2%)	14.2% (7.6%; 26.4%)
Other and unspecified	All	2,527	76.1% (74.3%; 77.9%)	66.4% (64.4%; 68.5%)	60.8% (58.6%; 63.1%)	58.4% (56.0%; 60.8%)	56.3% (53.8%; 58.9%)
	I	1,199	92.8% (91.0%; 94.6%)	87.5% (85.2%; 89.9%)	83.6% (80.8%; 86.4%)	81.7% (78.7%; 84.9%)	80.0% (76.5%; 83.7%)
	II	170	78.5% (71.9%; 85.6%)	70.3% (62.8%; 78.8%)	65.9% (57.7%; 75.3%)	62.0% (53.2%; 72.2%)	58.0% (48.4%; 69.6%)
	III	380	73.7% (69.1%; 78.5%)	59.4% (54.2%; 65.0%)	48.1% (42.7%; 54.1%)	43.4% (37.8%; 49.7%)	40.3% (34.5%; 47.0%)

Net Survival Probability, 2020-2024							
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**
	IV	446	40.5% (36.1%; 45.5%)	24.3% (20.5%; 28.8%)	17.2% (13.8%; 21.5%)	14.6% (11.3%; 18.8%)	11.8% (8.6%; 16.3%)
	X/NA	333	65.0% (59.7%; 70.8%)	52.7% (47.0%; 59.0%)	48.3% (42.5%; 55.0%)	46.7% (40.6%; 53.8%)	45.5% (39.0%; 53.0%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Corpus uteri cancer survival trends: by tumour stage

5.1.1. Corpus uteri cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024

		Net Survival Probability			
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	All	8,453	92.3% (91.6%; 93.0%)	83.4% (82.4%; 84.4%)	79.3% (78.0%; 80.5%)
	I	4,540	99.0% (98.5%; 99.6%)	96.1% (95.1%; 97.1%)	93.7% (92.3%; 95.1%)
	II	547	96.5% (94.4%; 98.7%)	85.5% (81.6%; 89.6%)	78.6% (73.7%; 83.9%)
	III	843	85.4% (82.8%; 88.0%)	59.9% (56.3%; 63.7%)	51.1% (47.2%; 55.2%)
	IV	380	54.3% (49.4%; 59.7%)	28.1% (23.7%; 33.3%)	21.2% (17.1%; 26.2%)
	X/NA	2,148	86.4% (84.8%; 88.0%)	75.0% (72.9%; 77.3%)	70.0% (67.5%; 72.7%)
2010-2014	All	7,131	91.3% (90.5%; 92.0%)	82.9% (81.8%; 84.0%)	80.0% (78.6%; 81.3%)
	I	4,724	98.7% (98.2%; 99.3%)	95.8% (94.8%; 96.9%)	94.7% (93.3%; 96.1%)
	II	386	90.6% (87.2%; 94.1%)	80.3% (75.2%; 85.7%)	75.0% (68.9%; 81.7%)
	III	704	81.2% (78.1%; 84.4%)	56.6% (52.7%; 60.9%)	48.6% (44.4%; 53.2%)
	IV	439	52.8% (48.2%; 57.8%)	27.1% (23.0%; 31.9%)	21.3% (17.4%; 26.0%)
	X/NA	882	78.4% (75.5%; 81.4%)	63.3% (59.6%; 67.2%)	57.1% (52.9%; 61.7%)
2015-2019	All	7,056	91.3% (90.5%; 92.1%)	83.7% (82.6%; 84.8%)	80.7% (79.3%; 82.0%)
	I	4,756	99.3% (98.8%; 99.8%)	96.6% (95.6%; 97.6%)	95.3% (93.9%; 96.7%)
	II	375	91.6% (88.3%; 95.1%)	80.2% (75.1%; 85.7%)	74.9% (68.8%; 81.5%)
	III	826	84.8% (82.1%; 87.5%)	65.5% (61.9%; 69.3%)	57.4% (53.3%; 61.8%)

Period	Stage	Net Survival Probability							
		N at risk	1-y	(95%CI)	3-y	(95%CI)	5-y	(95%CI)	
	IV	539	50.2%	(46.0%; 54.8%)	24.8%	(21.2%; 29.0%)	18.1%	(14.8%; 22.0%)	
	X/NA	564	72.6%	(68.7%; 76.7%)	59.5%	(54.9%; 64.4%)	55.0%	(49.8%; 60.7%)	
2020-2024	**All**	6,851	91.3%	(90.5%; 92.1%)	84.4%	(83.2%; 85.6%)	82.6%	(81.0%; 84.3%)	
	I	4,654	99.2%	(98.6%; 99.7%)	98.1%	(97.1%; 99.1%)	98.3%	(96.5%; 100.1%)	
	II	386	93.6%	(90.6%; 96.8%)	83.7%	(78.6%; 89.1%)	84.0%	(77.1%; 91.5%)	
	III	866	85.8%	(83.3%; 88.5%)	66.7%	(62.9%; 70.7%)	59.0%	(54.0%; 64.4%)	
	IV	656	52.5%	(48.7%; 56.6%)	29.3%	(25.6%; 33.5%)	20.8%	(17.0%; 25.4%)	
	X/NA	290	65.2%	(59.4%; 71.4%)	42.4%	(36.0%; 50.0%)	37.7%	(29.9%; 47.5%)	

5.2. Corpus uteri cancer survival trends: by tumour type and tumour stage

5.2.1. Corpus uteri cancer survival trends by type and stage: number at risk and net survival probabilities, 2004-2024

Period	Type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	Endometrioid carcinoma	**All**	5,528	96.3% (95.6%; 96.9%)	90.6% (89.5%; 91.7%)	87.0% (85.6%; 88.4%)
		I	3,530	99.8% (99.2%; 100.3%)	97.7% (96.6%; 98.8%)	95.8% (94.3%; 97.3%)
		II	392	98.5% (96.4%; 100.7%)	91.4% (87.3%; 95.7%)	85.2% (79.6%; 91.1%)
		III	472	88.6% (85.5%; 91.8%)	69.7% (65.1%; 74.6%)	62.3% (57.2%; 67.9%)
		IV	168	61.5% (54.4%; 69.6%)	34.5% (27.6%; 43.0%)	25.3% (19.1%; 33.6%)
		X/NA	966	92.4% (90.4%; 94.4%)	84.1% (81.1%; 87.2%)	78.3% (74.5%; 82.2%)
	Serous carcinoma	**All**	402	86.0% (82.4%; 89.9%)	53.7% (48.6%; 59.4%)	44.9% (39.6%; 50.9%)
		I	115	95.9% (91.0%; 101.0%)	85.6% (77.6%; 94.5%)	80.4% (70.5%; 91.8%)
		II	27	N<50	N<50	N<50
		III	122	86.4% (80.0%; 93.3%)	43.7% (35.3%; 54.1%)	31.6% (23.7%; 42.2%)
		IV	58	66.9% (55.6%; 80.6%)	27.5% (17.8%; 42.4%)	22.8% (13.8%; 37.6%)
		X/NA	80	83.2% (74.8%; 92.4%)	43.8% (33.5%; 57.1%)	35.2% (25.5%; 48.5%)
	Other and unspecified	**All**	2,529	84.5% (82.9%; 86.0%)	72.3% (70.3%; 74.4%)	67.6% (65.3%; 70.0%)
		I	895	96.5% (94.9%; 98.1%)	90.9% (88.2%; 93.8%)	86.9% (83.3%; 90.6%)
		II	128	91.3% (85.6%; 97.3%)	75.9% (67.2%; 85.6%)	68.6% (58.4%; 80.5%)
		III	249	78.8% (73.5%; 84.4%)	48.9% (42.6%; 56.1%)	39.3% (33.0%; 46.9%)
		IV	154	41.6% (34.3%; 50.4%)	21.3% (15.5%; 29.3%)	15.9% (10.7%; 23.6%)
		X/NA	1,106	81.1% (78.7%; 83.6%)	69.0% (66.0%; 72.3%)	65.1% (61.6%; 68.7%)
2010-2014	Endometrioid carcinoma	**All**	5,001	95.9% (95.2%; 96.7%)	91.3% (90.2%; 92.5%)	89.6% (88.2%; 91.1%)
		I	3,721	99.6% (99.1%; 100.2%)	98.3% (97.3%; 99.4%)	98.1% (96.7%; 99.6%)

Period	Type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	269	95.6% (92.3%; 99.0%)	89.3% (83.8%; 95.2%)	86.4% (79.3%; 94.1%)
		III	416	84.0% (80.3%; 88.0%)	65.9% (60.9%; 71.3%)	58.5% (53.1%; 64.5%)
		IV	148	59.5% (51.8%; 68.2%)	39.0% (31.5%; 48.4%)	32.8% (25.3%; 42.5%)
		X/NA	447	88.4% (85.0%; 91.9%)	74.4% (69.5%; 79.6%)	68.1% (62.0%; 74.9%)
	Serous carcinoma	All	476	84.4% (80.8%; 88.1%)	59.3% (54.5%; 64.6%)	49.3% (44.0%; 55.1%)
		I	218	96.1% (92.7%; 99.6%)	82.1% (75.8%; 89.0%)	74.3% (66.6%; 82.8%)
		II	24	N<50	N<50	N<50
		III	98	80.4% (72.2%; 89.5%)	42.4% (32.9%; 54.7%)	25.5% (17.1%; 38.0%)
		IV	80	69.5% (59.7%; 80.9%)	28.4% (19.6%; 41.1%)	20.6% (12.7%; 33.4%)
		X/NA	56	65.1% (53.3%; 79.6%)	42.9% (30.7%; 59.8%)	34.6% (22.9%; 52.2%)
	Other and unspecified	All	1,662	79.1% (77.0%; 81.2%)	64.4% (61.8%; 67.1%)	59.7% (56.8%; 62.8%)
		I	789	95.2% (93.4%; 97.2%)	87.7% (84.7%; 90.9%)	84.2% (80.3%; 88.3%)
		II	93	77.2% (68.5%; 87.0%)	58.4% (48.0%; 71.2%)	47.2% (36.5%; 61.1%)
		III	190	75.4% (69.2%; 82.2%)	43.4% (36.4%; 51.7%)	39.0% (31.8%; 47.8%)
		IV	211	41.7% (35.4%; 49.1%)	18.2% (13.5%; 24.5%)	13.2% (9.1%; 19.4%)
		X/NA	379	68.5% (63.7%; 73.7%)	53.0% (47.5%; 59.1%)	47.3% (41.4%; 54.0%)
2015-2019	Endometrioid carcinoma	All	5,061	96.4% (95.8%; 97.1%)	93.1% (92.0%; 94.2%)	91.2% (89.8%; 92.7%)
		I	3,844	100.5% (100.1%; 101.0%)	99.8% (98.8%; 100.8%)	99.4% (97.9%; 100.8%)
		II	243	96.6% (93.3%; 99.9%)	88.6% (82.9%; 94.6%)	83.7% (76.5%; 91.6%)
		III	484	89.2% (86.1%; 92.4%)	78.2% (73.8%; 82.9%)	69.8% (64.5%; 75.6%)
		IV	196	56.9% (50.2%; 64.6%)	37.5% (30.9%; 45.6%)	34.0% (27.2%; 42.4%)
		X/NA	294	81.4% (76.5%; 86.6%)	70.4% (64.2%; 77.1%)	64.0% (56.7%; 72.2%)
	Serous carcinoma	All	622	82.0% (78.8%; 85.4%)	54.9% (50.7%; 59.4%)	46.8% (42.4%; 51.6%)
		I	250	98.6% (96.0%; 101.2%)	81.3% (75.6%; 87.5%)	74.4% (67.6%; 81.9%)

Period	Type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	45	N<50	N<50	N<50
		III	145	86.2% (80.2%; 92.6%)	46.6% (38.7%; 56.2%)	37.5% (29.6%; 47.5%)
		IV	128	57.8% (49.7%; 67.3%)	23.0% (16.6%; 32.0%)	9.0% (5.1%; 16.0%)
		X/NA	54	39.8% (28.2%; 56.1%)	21.0% (12.0%; 36.8%)	19.3% (10.1%; 37.0%)
	Other and unspecified	All	1,380	76.6% (74.2%; 79.0%)	62.0% (59.1%; 65.0%)	57.0% (53.8%; 60.4%)
		I	665	92.5% (90.1%; 94.9%)	83.7% (80.2%; 87.4%)	78.9% (74.5%; 83.5%)
		II	87	75.8% (66.6%; 86.4%)	64.9% (53.9%; 78.1%)	57.0% (45.2%; 71.8%)
		III	197	72.9% (66.6%; 79.8%)	48.2% (41.1%; 56.5%)	40.8% (33.5%; 49.8%)
		IV	216	39.4% (33.2%; 46.6%)	14.1% (10.1%; 19.9%)	8.8% (5.5%; 14.3%)
		X/NA	216	68.6% (62.3%; 75.7%)	53.6% (46.6%; 61.8%)	51.4% (43.6%; 60.6%)
2020-2024	Endometrioid carcinoma	All	4,982	96.5% (95.8%; 97.2%)	93.8% (92.7%; 95.0%)	93.5% (91.7%; 95.3%)
		I	3,823	100.2% (99.7%; 100.7%)	101.0% (100.0%; 102.0%)	101.8% (99.9%; 103.7%)
		II	258	96.9% (93.8%; 100.1%)	91.1% (85.5%; 97.1%)	96.4% (89.4%; 103.9%)
		III	506	91.2% (88.3%; 94.2%)	78.2% (73.5%; 83.2%)	73.3% (66.7%; 80.6%)
		IV	255	62.4% (56.6%; 68.9%)	40.5% (34.2%; 48.0%)	28.5% (21.9%; 37.2%)
		X/NA	140	75.9% (68.5%; 84.2%)	55.0% (45.4%; 66.6%)	50.6% (38.6%; 66.4%)
	Serous carcinoma	All	725	80.4% (77.3%; 83.6%)	59.1% (54.9%; 63.5%)	50.3% (45.1%; 55.9%)
		I	299	97.1% (94.3%; 99.9%)	86.6% (81.1%; 92.4%)	81.1% (73.5%; 89.5%)
		II	45	N<50	N<50	N<50
		III	177	82.1% (76.1%; 88.4%)	52.8% (44.8%; 62.3%)	37.8% (28.4%; 50.4%)
		IV	171	52.3% (45.2%; 60.6%)	24.3% (18.1%; 32.7%)	15.5% (9.8%; 24.6%)
		X/NA	33	N<50	N<50	N<50
	Other and unspecified	All	1,147	75.4% (72.8%; 78.2%)	59.2% (55.9%; 62.7%)	55.0% (50.8%; 59.6%)
		I	534	93.2% (90.6%; 95.9%)	83.4% (79.1%; 87.8%)	81.9% (75.8%; 88.5%)

Period	Type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	83	81.2% (72.4%; 91.0%)	65.9% (54.3%; 80.0%)	53.7% (37.1%; 77.8%)
		III	183	74.5% (68.1%; 81.5%)	48.0% (40.2%; 57.2%)	39.4% (31.0%; 50.2%)
		IV	230	41.6% (35.6%; 48.7%)	20.4% (15.4%; 27.1%)	16.2% (11.0%; 23.8%)
		X/NA	117	58.0% (49.2%; 68.4%)	37.9% (28.7%; 50.1%)	31.6% (21.2%; 47.2%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Corpus uteri cancer mortality: by region

6.1.1. Corpus uteri cancer mortality by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Belgium	0	0	0	0	0	0	0	0	2	0	1	6	19	18	25	32	49	50	16	7	225	3.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.3]	[1.5]	[5.0]	[5.3]	[8.4]	[13.0]	[28.1]	[37.4]	[22.6]	[33.6]	[3.8]	(2.8; 3.6)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	4	1	1	0	7	1.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.0]	[0.0]	[0.0]	[31.1]	[10.2]	[17.6]	[0.0]	[1.1]	(0.3; 2.3)
Flanders	0	0	0	0	0	0	0	0	1	0	1	4	11	15	16	24	33	38	13	6	162	3.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.4]	[1.7]	[4.8]	[7.4]	[9.1]	[16.0]	[30.2]	[44.5]	[29.5]	[49.0]	[4.7]	(3.1; 4.3)
Wallonia	0	0	0	0	0	0	0	0	1	0	0	2	8	2	9	8	12	11	2	1	56	2.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[0.0]	[1.6]	[6.5]	[1.8]	[9.0]	[10.3]	[23.1]	[28.4]	[9.4]	[15.4]	[3.0]	(1.9; 3.3)

7.1. Corpus uteri cancer mortality trends: by region

7.1.1. Corpus uteri cancer mortality trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	180	186	181	191	219	198	210	201	188	214	228	209	230	232	238	233	227	261	216	225		
	CR	3.4	3.5	3.4	3.5	4.0	3.6	3.8	3.6	3.3	3.8	4.0	3.7	4.0	4.0	4.1	4.0	3.9	4.5	3.7	3.8		
	ESR2013	3.4	3.4	3.4	3.4	3.9	3.5	3.6	3.4	3.2	3.6	3.7	3.4	3.7	3.7	3.7	3.4	3.5	4.0	3.2	3.2	0.0 (-0.5; 0.5)	2004-2023
Brussels	**N**	18	14	14	15	21	11	7	17	17	12	14	15	21	15	14	15	16	19	17	7		
	CR	3.5	2.7	2.6	2.8	3.9	2.0	1.2	2.9	2.9	2.0	2.3	2.5	3.5	2.5	2.3	2.4	2.6	3.1	2.7	1.1		
	ESR2013	3.5	2.8	2.8	2.7	4.0	2.3	1.2	3.4	3.2	2.2	2.9	3.1	4.2	2.8	2.6	2.6	3.4	3.8	3.4	1.3	-0.4 (-3.0; 2.3)	2004-2023
Flanders	**N**	117	132	129	139	154	141	152	138	130	152	166	143	149	162	163	161	151	172	143	162		
	CR	3.8	4.3	4.2	4.5	4.9	4.5	4.8	4.3	4.0	4.7	5.1	4.4	4.5	4.9	4.9	4.8	4.5	5.1	4.2	4.7		
	ESR2013	3.9	4.3	4.1	4.3	4.7	4.3	4.5	4.0	3.8	4.3	4.4	3.8	3.9	4.2	4.2	3.9	3.8	4.3	3.5	3.7	-0.6 (-1.1; 0.0)	2004-2023
Wallonia	**N**	45	40	38	37	44	46	51	46	41	50	48	51	60	55	61	57	60	70	56	56		
	CR	2.6	2.3	2.2	2.1	2.5	2.6	2.8	2.5	2.3	2.7	2.6	2.8	3.3	3.0	3.3	3.1	3.2	3.8	3.0	3.0		
	ESR2013	2.6	2.1	2.2	2.1	2.4	2.6	2.7	2.5	2.1	2.7	2.4	2.7	3.2	2.8	2.9	2.7	3.0	3.5	2.6	2.6	1.5 (0.6; 2.3)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026